This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please **amend** the claims as follows:

Claim 1. (Currently Amended) ~~Compounds~~ A compound of the formula I



I

in which

R^1 is H, A or SO_2A,

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E is $R^2C{=}CR^4$ or $R^2R^3C\text{-}CR^4R^5$,
in which
R^2, R^3, R^4 and R^5 are selected, independently, from
~~H~~, A, cycloalkyl having from 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nN(R^6)Ar$, $(CH_2)_nN(R^6)Het$, $(CH_2)_nN(Ar)_2$, $(CH_2)_nN(Het)_2$, $(CH_2)_nCOOR^6$, $(CH_2)_nCOOAr$, $(CH_2)_nCOOHet$, $(CH_2)_nCON(R^6)_2$, $(CH_2)_nCON(R^6)Ar$, $(CH_2)_nCON(R^6)Het$, $(CH_2)_nCON(Ar)_2$, $(CH_2)_nCON(Het)_2$, $(CH_2)_nNR^6COR^6$, $(CH_2)_nNR^6CON(R^6)_2$, $(CH_2)_nNR^6SO_2A$, $(CH_2)_nSO_2N(R^6)_2$, $(CH_2)_nSO_2NR^6(CH_2)_mAr$,

$(CH_2)_nSO_2NR^6(CH_2)_mHet$, $(CH_2)_nS(O)_wR^6$, $(CH_2)_nS(O)_wAr$, $(CH_2)_nS(O)_wHet$, $(CH_2)_nOOCR^6$, $(CH_2)_nHet$, $(CH_2)_nAr$, $(CH_2)_nCOR^6$, $(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$, $(CH_2)_nS(CH_2)_mAr$, $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)CO(CH_2)_mHet$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$, $(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$, $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$, $CH=CHCH_2NR^6Het$, $CH=CHCH_2N(R^6)_2$, $CH=CHCH_2OR^6$, $(CH_2)_nN(COOR^6)COOR^6$, $(CH_2)_nN(CONH_2)COOR^6$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^6)COOR^6$, $(CH_2)_nN(CH_2CONH_2)COOR^6$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^6COR^6$, $(CH_2)_nCHR^6COOR^6$, $(CH_2)_nCHR^6CH_2OR^6$, $(CH_2)_nOCN$ or $(CH_2)_nNCO$, in which

R^6 is selected, independently, from H, A or cycloalkyl having from 3 to 7 carbon atoms,

Het is a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical which is unsubstituted or mono- or poly-substituted by A, Hal, NO_2, CN, OR^6, $N(R^6)_2$, $COOR^6$, $CON(R^6)_2$,

NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, $SO_2N(R^6)_2$, $S(O)_wA$ and/or $OOCR^6$,

Ar is an aromatic hydrocarbon radical having from 6 to 14 carbon atoms which is unsubstituted or mono- or polysubstituted by A, Hal, NO_2, CN, OR^6, $N(R^6)_2$, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, $SO_2N(R^6)_2$, $S(O)_wA$ and/or $OOCR^6$,

w is 0, 1, 2 or 3, and

n and m, independently of one another, are 0, 1, 2, 3, 4 or 5;

X^1 is $(CHR^7)_g$ or $(CHR^7)_h$-Q-$(CHR^8)_k$, in which

Q is selected from O, S, N-R^6, $(O\text{-}CHR^7)_g$, $(CHR^7\text{-}O)_g$, $CR^9=CR^{10}$, $(O\text{-}CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}\text{-}O)_g$, C=O, C=S, $C=NR^6$, $CH(OR^6)$, $C(OR^6)(OR^6)$, C(=O)O, OC(=O), OC(=O)O, $C(=O)N(R^6)$, $N(R^6)C(=O)$, $C(=S)N(R^6)$, $N(R^6)C(=S)$, $OC(=O)N(R^6)$, $N(R^6)C(=O)O$, CH=N-O, $CH=N\text{-}NR^6$, $OC(O)NR^6$, $NR^6C(O)O$, S=O, SO_2, SO_2NR^6 and NR^6SO_2,

g is 1, 2, 3, 4, 5 or 6,

h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6, and

R^7, R^8, R^9, R^{10} and R^{12}, independently of one another, are as defined for R^2 to R^5;

p is 0, 1, 2 or 3,

E is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$ or cycloalkyl having from 3 to 7 carbon atoms,

G is an optionally substituted alkylene radical having from 1 to 4 carbon atoms, where the substituents are selected from the meanings indicated for R^4,

or

E and

G, together with the N atom to which they are bonded, are an unsubstituted or substituted 5-, 6- or 7-membered, mono- or bicyclic heterocyclic radical, which may have 1, 2 or 3 further heteroatoms selected from N, O and S,

X^2 is a bond or is selected, independently, from the meanings indicated for X^1,

Z is H or is a saturated, mono- or polyethylenically unsaturated or aromatic carbocyclic radical having from 5 to 10 carbon atoms or a saturated, mono- or polyethylenically unsaturated or aromatic heterocyclic radical having from 4 to 9 carbon atoms, where the carbocyclic or heterocyclic radical may be mono- or polysubstituted, where the substituents are selected, independently of one another, from the meanings of R^2 to R^5 other than H, and where the heterocyclic radical contains from 1 to 4 heteroatoms selected, independently of one another, from N, O and S,

and

Hal is F, Cl, Br or I,

~~and~~ or a pharmaceutically ~~usable derivatives, salts, solvates and stereoisomers and mixtures~~ acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 2. (Currently Amended) ~~Compounds~~ The compound of the formula I according to Claim 1, in which

A is straight-chain alkyl having from 1 to 4 carbon atoms or branched alkyl having from 3 to 6 carbon atoms, and

D-E is $R^2C=CR^4$ or $R^2R^3C\text{-}CR^4R^5$, ~~in particular $R^2C=CR^4$~~, in which R^2, R^3 and R^5 are selected, independently, from ~~H~~, A and cycloalkyl having from 3 to 7 carbon atoms, and R^4 is Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nCOOR^6$, $(CH_2)_nCON(R^6)_2$, $(CH_2)_nNR^6COR^6$, $(CH_2)_nNR^6CON(R^6)_2$, $(CH_2)_nNR^6SO_2A$, $(CH_2)_nSO_2N(R^6)_2$, $(CH_2)_nS(O)_wA$, $(CH_2)_nOOCR^6$, $(CH_2)_nCOR^6$, $(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$, $(CH_2)_nS(CH_2)_mAr$, $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)CO(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$,

$(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$, $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$, $(CH_2)_nN(COOR^6)COOR^6$, $(CH_2)_nN(CONH_2)COOR^6$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^6)COOR^6$, $(CH_2)_nN(CH_2CONH_2)COOR^6$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^6COR^6$, $(CH_2)_nCHR^6COOR^6$ or $(CH_2)_nCHR^6CH_2OR^6$ ~~and in particular Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nCOOR^6$, $(CH_2)_nCON(R^6)_2$, $(CH_2)_nSO_2N(R^6)_2$ or $(CH_2)_nS(O)_wA$~~,

m is 0, 1, 2, 3, 4 or 5 and

n is ~~0, 1, 2 or 3 and in particular~~ 0 or 1;

X^1 is $(CHR^7)_g$ or Q-$(CHR^8)_k$, in which

Q is selected from O, S, N-R^6, (O-$CHR^7)_g$, (CHR^7-O)$_g$, $CR^9=CR^{10}$, (O-$CHR^9CHR^{10})_g$, (CHR^9CHR^{10}-O)$_g$, C=O, C=S, $C=NR^6$, $C(OR^6)(OR^6)$, C(=O)O, OC(=O), OC(=O)O, $C(=O)N(R^6)$, $N(R^6)C(=O)$, $OC(=O)N(R^6)$, $N(R^6)C(=O)O$, CH=N-O, $CH=N-NR^6$, $OC(O)NR^6$, $NR^6C(O)O$, S=O, SO_2, SO_2NR^6 and NR^6SO_2,

g is ~~1, 2, 3, 4, 5 or 6 and in particular~~ 2, 3 or 4,

k is ~~0, 1, 2, 3, 4, 5 or 6 and in particular~~ 1, 2 or 3, and

R^7, R^8, R^9 and R^{10} are selected, independently, from the meanings indicated for R^2 to R^5;

X^2 is a bond or independently is $(CHR^7)_g$ or Q-$(CHR^8)_k$, in which

Q is selected from O, S, N-R^6, $(O\text{-}CHR^7)_g$, $(CHR^7\text{-}O)_g$, $(O\text{-}CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}\text{-}O)_g$, C=O, $CH(OR^6)$, C(=O)O, OC(=O), $C(=O)N(R^6)$, $N(R^6)C(=O)$,S=O, SO_2, SO_2NR^6 and NR^6SO_2, where

g in X^2 is ~~preferably~~ 1 or 2 and k in X^2 is ~~preferably~~ 0 or 1, and

R^{12} is selected, independently, from the meanings of R^4 other than H ~~and in particular, independently, is F, Cl, Br, I, CN, NO_2, NH_2, CF_3, OCF_3, C(NH)NOH or SO_2CH_3,~~

~~and~~ or a pharmaceutically ~~usable derivatives, salts, solvates and stereoisomers and mixtures~~ acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 3. (Currently Amended) ~~Compounds~~ The compound according to Claim 1, selected from compounds of the formula Ia,



Ia

in which

R^1, D-E and Z are as defined above, and in which

X^1 is $(CHR^7)_g$ or $(CHR^7)_h$-Q-$(CHR^8)_k$, in which

Q is selected from O, S, N-R^6, $(O\text{-}CHR^7)_g$, $(CHR^7\text{-}O)_g$, $CR^9{=}CR^{10}$, $(O\text{-}CHR^9CHR^{10})_g$, $(CHR^9CHR^{10}\text{-}O)_g$, C=O, C=S, $C{=}NR^6$, $CH(OR^6)$,

$C(OR^6)(OR^6)$, C(=O)O, OC(=O), OC(=O)O, $C(=O)N(R^6)$, $N(R^6)C(=O)$, $OC(=O)N(R^6)$, $N(R^6)C(=O)O$, CH=N-O, $CH=N-NR^6$, $OC(O)NR^6$, $NR^6C(O)O$, S=O, SO_2, SO_2NR^6 and NR^6SO_2,

g is 1, 2, 3, 4, 5 or 6,

h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6, and

R^6 is selected, independently, from H, A or cycloalkyl having from 3 to 7 carbon atoms,

R^7, R^8, R^9 and R^{10} are selected, independently, from the meanings indicated for R^2 to R^5;

Y is CH, N, COR^{11}, CSR^{11}, an unsubstituted or substituted, spiro-linked carbocyclic radical having from 5 to 7 carbon atoms or an unsubstituted or substituted, spiro-linked, 5-, 6- or 7-membered heterocyclic radical having from 1 to 3 heteroatoms selected from N, S or O,

R^{11} is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$ or cycloalkyl having from 3 to 7 carbon atoms,

X^2 is ~~a bond or is selected, independently, from the meanings indicated for X^1, and is preferably~~ a bond or O, S, N-R^7, CH_2 or CH_2CH_2,

p, q and r, independently of one another, are 0, 1, 2 or 3

and

Hal is F, Cl, Br or I, and

R^{12} and R^{13}, ~~independently of one another, are selected from the meanings of R^4 other than H and~~ are ~~preferably~~, independently of one another, Hal, CN, NO_2, OR^6, $N(R^6)_2$, NO_2, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ and/or C(NH)NOH,

~~and~~ or a pharmaceutically ~~usable derivatives, salts, solvates and stereoisomers and mixtures~~ acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 4. (Currently Amended) ~~Compounds~~ A compound ~~according to Claim 1, selected from~~ of the formula

a) 6-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

b) 6-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

c) 6-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

d) 4-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

e) 4-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

f) 4-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

g) 5-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

h) 5-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

i) 5-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;

j) 5-{3-[4-(4-cyanophenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

k) 5-{4-[3-(3-cyano-1H-indol-6-yl)propyl]piperazin-1-yl}benzofuran-2-carboxamide;

l) 5-{3-[4-(2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

m) 5-{4-[3-(3-cyano-1H-indol-4-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;

n) 5-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-benzofuran-2-carboxamide;

o) 5-{3-[4-(1H-indol-4-yl)-piperazin-1-yl]propyl}-1-methanesulfonyl-1H-indole-3-carbonitrile;

p) 5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;

q) 5-[3-(4-benzo[1,2,5]thiadiazol-4-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

r) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carboxamide;

s) 5-[3-(4-quinolin-8-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

t) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

u) 1-methanesulfonyl-5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;

v) 5-{3-[4-(1H-indol-4-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

w) 5-{3-[4-(1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

x) 5-{3-[4-(5-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

y) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carbonitrile;

z) 5-{3-[4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

aa) 5-{3-[4-(4-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;

bb) 5-[3-(4-benzo[d]isothiazol-3-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

cc) 4-{1-[3-(3-cyano-1H-indol-6-yl)propyl]piperidin-4-yloxy}benzamide;

dd) 6-{3-[4-(2-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-

carbonitrile;

ee) 6-{3-[4-(4-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

ff) 6-{3-[4-(4-cyano-2-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

gg) 4-[3-(4-pyrazol-1-ylmethyl-1-piperidyl)propyl]-1H-indole-3-carbonitrile;

hh) N-(6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)acetamide;

ii) 5-{3-[(pyridin-3-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;

jj) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

kk) 5-[3-(4-pyrimidin-2-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;

ll) 5-{3-[(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;

mm) 5-{3-[4-(3-methoxyphenyl)-3-methylpiperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

nn) 5-{3-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

oo) N-(4-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-ylmethyl}-phenyl)acetamide;

pp) 5-{3-[4-(4-pyridin-3-ylthiazol-2-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

qq) ethyl 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-thiazole-4-carboxylate;

rr) 5-{3-[3-(2-oxopyrrolidin-1-yl)propylamino]propyl}-1H-indole-3-carbonitrile;

ss) ethyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate;

tt) 5-{3-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

uu) methyl (6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-

2H-chromen-3-yl)carbamate;

vv) 2-{4-[3-(3-cyano-1H-indol-5-yl)propyl]-piperazin-1-yl}thiazole-4-carboxamide;

ww) 4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazine-1- thiocarboxamide;

~~and derivatives, salts and solvates~~ or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 5. (Currently Amended) ~~Process~~ A process for the preparation of ~~compounds~~ a compound of ~~the~~ formula I according to Claim 1 ~~and salts~~ or a salt thereof~~, characterised in that~~ comprising reacting

a) a compound of the formula II



II

in which

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R^1, D, E, R^{12}, p and X^1 are as defined in Claim 1,

b) ~~is reacted~~ with a compound of the formula III



III

in which

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1,

and optionally

c) converting the resultant compound of the formula I ~~is converted~~ into ~~one of it's salts~~ a salt by treatment with an acid.

Claim 6. (Currently Amended) ~~Process~~ A process for the preparation of a pharmaceutical composition, ~~characterised in that~~ comprising converting a compound of ~~the formula I according to~~ Claim 1 ~~and/or one of its~~ a ~~physiologically acceptable salts is converted~~ into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

Claim 7. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition~~,~~ ~~characterised by a content of~~ comprising at least one compound of ~~the formula I according to~~ Claim 1 ~~and/or one of its physiologically acceptable salts and/or one of its solvates~~ and a pharmaceutically acceptable carrier.

Claim 8. (Cancelled)

Claim 9. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and/or physiologically acceptable salts thereof as~~ A method for modulating the activity of an excitatory amino acid ~~antagonists~~ in a cell, comprising contacting said cell with a compound of claim 1.

Claim 10. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and physiologically acceptable salts and solvates thereof as~~ A method for modulating the activity of a glycine transporter ~~inhibitor~~ comprising contacting said transporter with a compound of claim 1.

Claim 11. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and physiologically acceptable salts thereof as~~ A method according to claim 9 wherein said compound antagonizes the activity of said excitatory amino acid

~~antagonists for combating neurodegenerative diseases, including cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses~~.

Claim 12. (Currently Amended) ~~Use of the compounds of the formula I according to Claim 1 for the preparation of a medicament for the prophylaxis and/or therapy of~~ A method for preventing or treating a 5HT-mediated disease ~~diseases in which 5HT plays a role~~ comprising administering to a host in need thereof a compound of claim 1.

Claim 13. (Currently Amended) ~~Use of the compounds of the formula I corresponding~~ A method according to Claim 12, ~~characterised in that the diseases are~~ wherein said disease is selected from the group comprising depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, brain and spinal cord trauma, obsessive-compulsive disorder, sleeping disorders, tardive dyskinesia, learning disorders, age-related memory disorders, eating disorders~~, such as bulimia~~, and/or sexual dysfunctions.

Claim 14. (Currently Amended) ~~Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of~~ A method for treating and/or preventing schizophrenia, depression, dementia, Parkinson's disease, Alzheimer's disease, Lewy bodies dementia, Huntington's disease, Tourette's syndrome, anxiety, learning and memory impairments, neurodegenerative diseases, ~~and other~~ cognitive impairments, ~~as well as~~ nicotine dependence ~~and~~ or pain comprising administering to a host in need thereof a compound of claim 1.

Claim 15. (Currently Amended) ~~Use of the compounds of the formula I according to Claim 1 and/or physiologically acceptable salts thereof for the preparation of a medicament~~ A method for combating neurodegenerative diseases, ~~including~~ cere-

brovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a compound of claim 1.

Claim 16. (Currently Amended) ~~Use of the compounds of the formula I according to Claim 1 and/or physiologically acceptable salts thereof~~ A method for combating neurodegenerative diseases, ~~including~~ cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a pharmaceutical composition of claim 7.

Claim 17. (Cancelled)

Claim 18. (Withdrawn, Currently Amended) ~~Compounds~~ A compound of the formula II



II

in which

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R^1, D, E, R^{12}, p and X^1 are as defined in Claim 1.

Claim 19. (Withdrawn, Currently Amended) ~~Compounds~~ A compound of the formula III



III

in which

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1.

Claim 20. (New) A compound of the formula Ia



Ia

wherein

R^1 is H, A or SO_2A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 1, 2, 3, 4, 5 or 6,

R^7 is selected, independently, from the meanings indicated for R^2 to R^5;

Y is CH or N,

q is 0,

p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13}, independently of one another, are selected from the meanings of R^4 other than H and are, independently of one another, Hal, CN, NO_2, OR^6, $N(R^6)_2$, NO_2, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ and/or C(NH)NOH, and

X^2-Z is selected from the group consisting of



in which

X^2 is a bond,

R^{14} is selected, independently, from Hal, A, $(CH_2)_nHet$, $(CH_2)_nAr$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nNHOA$, $(CH_2)_n(R^6)Het$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$,

w is 0, 1, 2 or 3,

t is 0, 1, 2, 3, 4 or 5, and

R' is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon atoms or SO_2A;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.

Claim 21. (New) A compound of the formula IIa



IIa

wherein R^1 and R^2 are as defined in claim 20; and

Y-Z is a radical of the formulae



or a radical of the formulae



or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.

Claim 22. (New) A compound of the formula Ia according to claim 20



Ia

wherein

R^1 is H or A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 3,

R^7 is selected, independently, from the meanings indicated for R^2 to R^5;

Y is CH or N,

q is 0,

p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13}, are, independently of one another, Hal, CN, NO_2, OR^6, $N(R^6)_2$, NO_2, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ and/or C(NH)NOH, and

X^2-Z is selected from the group consisting of



in which

X^2 is a bond,

R^{14} is selected, independently, from Hal, NO_2, OR^6, $N(R^6)_2$, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6, $NR^6CON(R^6)_2$, NR^6SO_2A, COR^6, SO_2NR^6, $S(O)_wA$, $OOCR^6$ and/or C(NH)NOH,

w is 0, 1, 2 or 3,

t is 1, 2, 3, and

R' is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon

atoms or SO_2A;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.